What clinical factors impact your upfront treatment decisions in transplant-ineligible MM?

My approach is to start with up-front adjustments in choice of drugs, dose, and schedule based upon many factors: age, organ function/other comorbidities, concurrent medications, insurance/other economic factors, personal physical mobility, and access to transportation, patient goals, etc.

Myeloma tr...

In general, one has to consider patient-related and disease-related factors while picking a therapeutic approach. Simplistically, we would consider RVd-lite for patients who have high-risk features in the TI setting and DRd for standard risk patients (or high risk patients with pre-existing neuropat...

The treatment selection depends on a combination of factors including the risk status based on the revised international staging system, presence of renal insufficiency, functional status of the patients, comorbidities as well as patient preferences. Other presenting features, particularly symptoms ...